This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
August 09, 2012 4:30 pm ET
David T. Hung - Chief Executive Officer, President and Executive Director
C. Patrick Machado - Chief Financial Officer, Principal Accounting Officer, Chief Business Officer and Secretary
Lynn Seely - Chief Medical Officer and Senior Vice President
Cheryl Cohen - Chief Commercial Officer
Kimberly Lee - ThinkEquity LLC, Research Division
Yaron Werber - Citigroup Inc, Research Division
Y. Katherine Xu - William Blair & Company L.L.C., Research Division
Geoffrey C. Porges - Sanford C. Bernstein & Co., LLC., Research Division
Lee Kalowski - Crédit Suisse AG, Research Division
Biren Amin - Jefferies & Company, Inc., Research Division
Raghuram Selvaraju - Aegis Capital Corporation, Research Division
Ling Wang - Summer Street Research Partners
Eric Schmidt - Cowen and Company, LLC, Research Division
Howard Liang - Leerink Swann LLC, Research Division
Good day, everyone, and welcome to Medivation's scheduled conference call. This call is being recorded. [Operator Instructions] I would now like to turn the call over to Anne Bowdidge, Senior Director of Investor Relations. Please go ahead.
Thank you for joining us. On the call today from Medivation are Dr. David Hung, President and CEO; Patrick Machado, Chief Business and Financial Officer; Dr. Lynn Seely, Chief Medical Officer; and Cheryl Cohen, Chief Commercial Officer. We issued a press release earlier today that you can find on our website at www.medivation.com.
Before we begin, I'd like to remind you that various remarks we make on this call contain forward-looking statements that are made under the Safe Harbor provisions of the securities laws, including statements regarding the potential future regulatory approval and commercialization of enzalutamide and the timing thereof; continued clinical development of enzalutamide; potential future clinical trial events or results; the therapeutic potential and safety profiles of our product candidates; our future opportunities and milestones; and financial guidance for the remainder of 2012, including projected revenue recognition, operating expenses, capital expenditures and receipt of development milestone payments.